Generic Ofev ( Nintedanib )

Order cheap Generic Ofev (Nintedanib) without dr prescription in the United States

In our USA pharmacy, you can buy Ofev without a prescription, with delivery across the USA within 2‑5 days. Discreet and anonymous packaging.
Ofev (nintedanib) is an oral tyrosine kinase inhibitor that targets multiple growth factor receptors involved in the pathogenesis of fibrotic lung diseases, including platelet‑derived growth factor receptors (PDGFR), fibroblast growth factor receptors (FGFR), and vascular endothelial growth factor receptors (VEGFR). By blocking these pathways, nintedanib reduces fibroblast proliferation, myofibroblast differentiation, and extracellular matrix deposition, thereby slowing the decline in lung function in patients with idiopathic pulmonary fibrosis (IPF), systemic sclerosis‑associated interstitial lung disease (SSc‑ILD), and chronic fibrosing interstitial lung diseases with a progressive phenotype (PF‑ILD).
Usual adult dose: The recommended dose is 150 mg orally twice daily, taken with food approximately 12 hours apart. For patients who cannot tolerate the 150 mg dose due to gastrointestinal side effects or liver enzyme elevations, a reduced dose of 100 mg twice daily may be used.
Dosage form: Soft gelatin capsules (100 mg and 150 mg).
Onset of action: The therapeutic benefit on lung function decline is observed over months; the full effect is evaluated after at least 12 months of continuous therapy.
Duration of action: The antifibrotic effect persists while on maintenance therapy; discontinuation leads to loss of benefit.
Alcohol consumption should be limited; heavy alcohol intake may increase the risk of liver toxicity and should be avoided during treatment.
Most common side effects: diarrhea, nausea, vomiting, abdominal pain, decreased appetite, weight loss, and elevated liver enzymes.
Would you like to try Ofev without a prescription?

General Information about Ofev

• INN (International Nonproprietary Name): Nintedanib
• Brand names available in the USA: Ofev® (Boehringer Ingelheim Pharmaceuticals, Inc.). No generic versions are currently available in the United States.
• ATC code: L01EX09
• Dosage forms and strengths: Soft gelatin capsules containing 100 mg or 150 mg of nintedanib.
• Manufacturers in USA: Boehringer Ingelheim Pharmaceuticals, Inc.
• Registration status in USA: Approved by the U.S. Food and Drug Administration (FDA) on October 15, 2014 for IPF (NDA 205832); subsequently approved for SSc‑ILD and chronic fibrosing ILDs with a progressive phenotype.
• OTC / Rx classification: Prescription only (Rx).

Mechanism of Action and Pharmacology

Nintedanib is a small‑molecule intracellular inhibitor that targets multiple receptor tyrosine kinases and non‑receptor kinases. It binds competitively to the adenosine triphosphate (ATP) binding pocket of platelet‑derived growth factor receptor (PDGFR) α and β, fibroblast growth factor receptor (FGFR) 1‑3, vascular endothelial growth factor receptor (VEGFR) 1‑3, and Fms‑like tyrosine kinase 3 (FLT3). By inhibiting these kinases, nintedanib blocks downstream signaling cascades that are critical for fibroblast proliferation, migration, and differentiation into myofibroblasts, as well as for the secretion of extracellular matrix proteins. This leads to a reduction in the fibrotic remodeling characteristic of interstitial lung diseases. Nintedanib also inhibits angiogenesis through VEGFR blockade, which may contribute to its antifibrotic effects. Following oral administration, the absolute bioavailability is approximately 4.7% when taken with food; taking nintedanib with food increases exposure by about 20% and improves tolerability. Peak plasma concentrations are reached 2‑4 hours after dosing. Nintedanib is metabolized primarily by hydrolytic ester cleavage and subsequent glucuronidation; cytochrome P450 enzymes play a minor role. The major route of elimination is fecal/biliary excretion of metabolites, with less than 1% of the dose excreted renally as unchanged drug. The terminal half‑life is approximately 10‑15 hours.

Indications

• Treatment of idiopathic pulmonary fibrosis (IPF) to slow the decline in forced vital capacity (FVC).
• Treatment of systemic sclerosis‑associated interstitial lung disease (SSc‑ILD) to slow the rate of decline in pulmonary function.
• Treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype (PF‑ILD) to slow the rate of decline in pulmonary function.

Important Warnings and Precautions

Ofev (nintedanib) carries a boxed warning for embryo‑fetal toxicity. Based on animal studies and its mechanism of action, nintedanib can cause fetal harm when administered to a pregnant woman. Pregnancy must be excluded before initiation of treatment, and women of childbearing potential must use effective contraception during and for at least 3 months after the last dose. Hepatotoxicity, including drug‑induced liver injury, has been reported. Liver function tests (ALT, AST, bilirubin) must be monitored prior to initiation, monthly for the first 3 months, and then periodically. Dose interruption or permanent discontinuation may be required for elevated liver enzymes. Arterial thromboembolic events, including myocardial infarction, have been observed; use with caution in patients with known cardiovascular risk. Bleeding events, including epistaxis and gastrointestinal bleeding, have occurred; monitor for bleeding and avoid use in patients with known bleeding risk unless the benefit outweighs the risk. Gastrointestinal perforation has been reported; discontinue therapy in patients who develop gastrointestinal perforation, and use with caution in patients with a history of abdominal surgery or diverticular disease. Diarrhea is very common (up to 62%) and may lead to dehydration; manage promptly with loperamide or dose reduction. Nausea and vomiting are also frequent and can be mitigated by taking each dose with food. Thrombocytopenia has been reported; monitor platelet counts periodically.

At‑risk groups

• Elderly: No dose adjustment is required based solely on age; however, the majority of patients in clinical trials were ≥65 years, and adverse events such as diarrhea and liver enzyme elevations may be more pronounced. Monitor closely.
• Pregnancy: Contraindicated. Nintedanib may cause fetal harm based on animal studies and its mechanism of action. Women of childbearing potential must have a negative pregnancy test before starting therapy and must use effective contraception during treatment and for 3 months after discontinuation.
• Breastfeeding: It is not known whether nintedanib is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment.
• Renal impairment: No dose adjustment is required for mild to moderate renal impairment (creatinine clearance ≥30 mL/min). Limited data are available in patients with severe renal impairment; use with caution.
• Hepatic impairment: Contraindicated in patients with moderate or severe hepatic impairment (Child‑Pugh B or C). In patients with mild hepatic impairment (Child‑Pugh A), no dose adjustment is required, but close monitoring of liver function is essential.
• Pediatric: Safety and efficacy have not been established in pediatric patients.
• Smokers: No clinically relevant effect of smoking on nintedanib exposure has been observed; however, smoking cessation should be strongly encouraged to preserve lung function.
• Bleeding risk: Use with caution in patients with known bleeding diathesis or those taking full‑dose anticoagulation or antiplatelet agents.

Driving and alcohol

Nintedanib may cause fatigue, dizziness, and somnolence, which can impair the ability to drive or operate machinery. Patients should avoid driving or engaging in hazardous activities until they know how the medication affects them. Alcohol consumption should be limited or avoided. Heavy alcohol intake may increase the risk of hepatotoxicity and exacerbate gastrointestinal adverse effects such as nausea, vomiting, and diarrhea.

Dosage Instructions

• Recommended dose: 150 mg orally twice daily, taken with food, approximately 12 hours apart.
• Dose reduction for intolerance: For patients who cannot tolerate the 150 mg twice‑daily dose due to persistent gastrointestinal symptoms or liver enzyme elevations, the dose may be reduced to 100 mg twice daily. If the 100 mg dose is still not tolerated, consider temporary interruption. After symptoms resolve, re‑escalation to the 150 mg dose may be attempted.
• Hepatic enzyme monitoring and adjustment: If AST or ALT >3 to ≤5× the upper limit of normal (ULN), interrupt or reduce the dose to 100 mg twice daily and monitor liver enzymes weekly. If AST/ALT >5× ULN or accompanied by signs/symptoms of liver injury, permanently discontinue.
• Management of diarrhea: At the first signs of diarrhea, ensure adequate hydration and consider loperamide; if diarrhea persists, dose interruption or reduction to 100 mg twice daily may be necessary.
• Administration: Take each dose with a full glass of water and with food. Swallow the capsules whole; do not crush, chew, or open them. Taking nintedanib with food improves absorption and reduces gastrointestinal side effects.
• Missed dose: If a dose is missed, skip the missed dose and take the next dose at the regular scheduled time. Do not take two doses at the same time to make up for a missed one.

Side Effects and Contraindications

Most common adverse reactions (incidence ≥5%): Diarrhea (62%), nausea (24%), vomiting (12%), abdominal pain (15%), decreased appetite (11%), weight loss (10%), and elevated liver enzymes (ALT elevation 5‑14%). These are most frequent during the first few months of therapy and often improve with dose reduction or symptomatic management.
Other clinically important adverse reactions: Fatigue, headache, hypertension, epistaxis, and peripheral edema. Thrombocytopenia (including severe cases) has been observed.
Serious adverse reactions: Hepatotoxicity with severe drug‑induced liver injury (including fatal cases); arterial thromboembolic events (myocardial infarction, stroke); gastrointestinal perforation; severe bleeding events; and embryo‑fetal toxicity.
Absolute contraindications: Known hypersensitivity to nintedanib, peanut, or soya (capsule shell contains soya lecithin); pregnancy; moderate or severe hepatic impairment (Child‑Pugh B or C).

Drug Interactions

• P‑glycoprotein (P‑gp) inhibitors (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin): Significantly increase nintedanib exposure. Concomitant use with strong P‑gp inhibitors should be avoided; if unavoidable, reduce the nintedanib dose to 100 mg twice daily and monitor closely for adverse effects.
• P‑glycoprotein (P‑gp) inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort): Decrease nintedanib exposure, potentially reducing efficacy. Avoid concomitant use.
• Anticoagulants and antiplatelet agents (e.g., warfarin, aspirin, clopidogrel, heparin, direct oral anticoagulants): Increased risk of bleeding; use with caution and monitor for signs of bleeding.
• Grapefruit juice and seville oranges: Potential for weak P‑gp inhibition; avoid large quantities of grapefruit juice during therapy.
• Alcohol: Heavy alcohol use may increase the risk of hepatotoxicity; limit or avoid.
• Nintedanib does not significantly inhibit or induce CYP enzymes; however, as a P‑gp substrate, interactions with P‑gp modulators are clinically relevant.

Practical Advice

• Take Ofev exactly as prescribed, twice daily with food. Swallow capsules whole with a full glass of water. Do not crush, chew, or open the capsules.
• If you miss a dose, skip it and take the next dose at the regular time. Never double a dose.
• Diarrhea is the most common side effect. At the first sign of loose stools, drink plenty of fluids and contact your healthcare provider. Over‑the‑counter loperamide (Imodium®) may be recommended. Do not self‑medicate without consulting your doctor.
• Monitor for signs of liver injury: yellowing of the skin or eyes, dark urine, light‑colored stools, severe nausea or vomiting, abdominal pain, or unexplained fatigue. Report these immediately.
• Women of childbearing potential must use effective contraception during treatment and for 3 months after the last dose. Report any pregnancy immediately.
• Use caution when driving or operating machinery until you know how Ofev affects you; fatigue and dizziness can occur.
• Limit alcohol consumption during treatment.
• Regular blood tests to check liver function and platelet counts are required. Keep all scheduled laboratory appointments.
• Avoid grapefruit juice and seville orange products.
• Store capsules at room temperature (20‑25°C / 68‑77°F) in the original container, protected from light and moisture. Keep out of reach of children.
• Never share this medication with anyone else; it is prescribed specifically for your condition.

Alternative Medications

• Pirfenidone (Esbriet®): Another oral antifibrotic agent that also slows lung function decline in IPF. It works via a different mechanism (inhibition of TGF‑β and TNF‑α) and has a distinct side‑effect profile (photosensitivity, nausea, rash). Pirfenidone and nintedanib are the only two FDA‑approved disease‑modifying therapies for IPF.
• Lung transplantation: The only definitive treatment for advanced fibrotic lung disease; antifibrotic therapy may be used as a bridge to transplant.
• Supportive care: Supplemental oxygen, pulmonary rehabilitation, immunizations (influenza, pneumococcal), and management of comorbidities are essential components of comprehensive care for interstitial lung disease.
• There are no other FDA‑approved pharmacologic alternatives; corticosteroids and other immunosuppressants are not recommended for IPF due to lack of benefit and potential harm.

Clinical Efficacy

The efficacy of nintedanib for IPF was demonstrated in two phase 3, randomized, double‑blind, placebo‑controlled trials (INPULSIS‑1 and INPULSIS‑2). In the pooled analysis, nintedanib 150 mg twice daily reduced the annual rate of decline in forced vital capacity (FVC) by approximately 50% compared with placebo (‑113.6 mL/year vs. ‑223.5 mL/year; p<0.001). The time to first acute exacerbation was also significantly prolonged. For systemic sclerosis‑associated ILD, the SENSCIS trial showed a 44% reduction in the annual rate of FVC decline with nintedanib compared with placebo (‑52.4 mL/year vs. ‑93.3 mL/year; p=0.04). For progressive fibrosing ILDs other than IPF, the INBUILD trial demonstrated a 57% reduction in the adjusted annual rate of FVC decline over 52 weeks (‑80.8 mL/year vs. ‑187.8 mL/year; p<0.001), with consistent benefit across diagnostic subgroups. Across all indications, nintedanib has been shown to slow disease progression and preserve lung function, with a well‑characterized and manageable safety profile.

Important:

Ofev (nintedanib) is a prescription antifibrotic medication that must be used under the supervision of a healthcare provider experienced in the management of interstitial lung diseases. It carries a boxed warning for embryo‑fetal toxicity; pregnancy must be excluded before starting therapy and women of childbearing potential must use effective contraception during treatment and for 3 months after discontinuation. Liver function tests must be monitored regularly, and the drug may need to be interrupted or permanently discontinued if significant liver injury occurs. Diarrhea, nausea, and vomiting are very common and require proactive management, including dose reduction when necessary. Do not stop taking Ofev without consulting your physician, as interruption may lead to loss of lung function benefit. Concomitant use of strong P‑glycoprotein inhibitors or inducers should be avoided when possible. Grapefruit juice and seville orange products should also be limited. This medication is contraindicated in patients with moderate or severe hepatic impairment and in pregnancy. Keep out of reach of children and never share this medication with others. If you experience signs of liver injury, severe or persistent gastrointestinal symptoms, signs of bleeding, or chest pain, seek immediate medical attention.

How to buy Generic Ofev no prescription U.S. Online Pharmacy